Shots:

• The P-IIIb PONENTE study evaluates the safety & efficacy of Fasenra (30mg- SC- q8w) in adult patients with sev. eosinophilic asthma on high-dose ICS + LABA & long-term use of OCS therapy with/out additional asthma controlled
• Results: 97% of patients maintained a low OCS dose of ≤5mg across blood eosinophil counts @6mos.- 3% of patients completed reduction phase to increase maintenance OCS dosage- exacerbation free (85%) compared to baseline (16%) @12mos.- improvement (18%) or no change (39%) in asthma control from the end of OCS-reduction to a maintenance phase
• Fasenra is currently approved as an add-on maintenance treatment for asthma & is approved for self-administration in the US- EU & other countries

| Ref: AstraZeneca | Image: Reuters